{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:24:35Z","timestamp":1778750675858,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant","award":["No. LYY21H310007"],"award-info":[{"award-number":["No. LYY21H310007"]}]},{"name":"the Medical and Health Science and Technology Project of Linping District, Hangzhou","award":["No. Yu2019001"],"award-info":[{"award-number":["No. Yu2019001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Low-molecular-weight heparin (LMWH) is widely used for thromboprophylaxis and treatment in hospitalized patients; however, LMWH-related severe clinical bleeding (LSCB) remains a major concern. Existing risk scales have been developed for oral anticoagulants and have limited applicability to LMWH, leaving clinicians without reliable bedside tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate the discriminatory performance of existing scales for predicting LSCB and develop a tailored nomogram for individualized risk prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      Hospitalized medical patients prescribed LMWH between July 2021 and August 2024 at three tertiary hospitals in Hangzhou, China were retrospectively analyzed. Each LSCB case was matched with three non-LSCB controls from the same department and period. The prevalence of LSCBs, bleeding sites, and clinical characteristics are described. Receiver operating characteristic (ROC) curves were used to assess the predictive performance of existing scales. Variables with\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.10 in univariate analysis were entered into logistic regression, a backward stepwise elimination (stay\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) was applied to identify independent predictors and subsequently incorporated into a nomogram. Discrimination, calibration, and external validation were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 22,096 patients, 369 (1.67%) developed LSCB, most commonly severe gastrointestinal bleeding (74.3%), with a mean onset of 5.68\u00a0days. A total of 1,089 patients with non-LSCB were matched as controls. Existing scales performed limited predictive value (AUC 0.52\u20130.68). Logistic regression identified 12 independent predictors: hypoproteinemia (albumin\u2009&lt;\u200930\u00a0g\/L), anemia (Hb\u2009&lt;\u200990\u00a0g\/L), active gastrointestinal ulcer, thrombocytopenia (platelets\u2009&lt;\u200975\u2009\u00d7\u200910\u2079\/L), coagulation abnormalities (PT or aPTT\u2009&gt;\u20091.2\u2009\u00d7\u2009ULN), cefoperazone\/latamoxef exposure\u2009&gt;\u20097\u00a0days, hypocalcemia ([Ca\n                      <jats:sup>2<\/jats:sup>\n                      \u207a]\u2009&lt;\u20092.10\u00a0mmol\/L), aspirin therapy, dual antiplatelet therapy, renal dysfunction (GFR\u2009&lt;\u200960\u00a0mL\/min), hepatic impairment (AST or ALT\u2009\u2265\u20093 or TBIL\u2009\u2265\u20092\u2009\u00d7\u2009ULN), and age\u2009&gt;\u200965\u00a0years. Odds ratios ranged from 6.16 (hypoproteinemia) to 1.47 (age\u2009&gt;\u200965\u00a0years). A nomogram, named LSCB-Score, incorporating these factors achieved AUC 0.890 in the derivation cohort. Calibration was good (Hosmer\u2013Lemeshow\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.312), and predictions closely matched the observations. External validation yielded an AUC of 0.876, confirming robustness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The existing scales for predicting LSCB lack accuracy in hospitalized patients. This newly developed nomogram (LSCB-Score) provides a practical framework for individualized bleeding risk assessment and facilitates safe management of LMWH in hospitals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-02070-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:01:16Z","timestamp":1765807276000},"page":"764-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond existing rating scales: development of a novel nomogram for predicting severe clinical bleeding associated with low-molecular-weight heparin in hospitalized medical patients"],"prefix":"10.1007","volume":"48","author":[{"given":"Zailin","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianrong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2070_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(08)60202-0","volume":"371","author":"AT Cohen","year":"2008","unstructured":"Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387\u201394.","journal-title":"Lancet"},{"key":"2070_CR2","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1097\/PTS.0000000000000900","volume":"18","author":"K Zhen","year":"2022","unstructured":"Zhen K, Dong F, Fang F, et al. Evaluation of in-hospital venous thromboembolism prevention and management system using hospital-level metrics: a nationwide cross-sectional survey in China. J Patient Saf. 2022;18:e626\u201332.","journal-title":"J Patient Saf"},{"key":"2070_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329:1924\u201333.","journal-title":"JAMA"},{"key":"2070_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-023-02858-y","volume":"56","author":"T Guan","year":"2023","unstructured":"Guan T, Laguna A, Soares A, et al. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies. J Thromb Thrombolysis. 2023;56:439\u201346.","journal-title":"J Thromb Thrombolysis"},{"key":"2070_CR5","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","volume":"111","author":"MA Crowther","year":"2008","unstructured":"Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:4871\u20139.","journal-title":"Blood"},{"key":"2070_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jama.292.1.89","volume":"292","author":"JL Petersen","year":"2004","unstructured":"Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89\u201396.","journal-title":"JAMA"},{"key":"2070_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12893-022-01652-6","volume":"22","author":"D Fu","year":"2022","unstructured":"Fu D, Li L, Li Y, et al. Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study. BMC Surg. 2022;22:243.","journal-title":"BMC Surg"},{"key":"2070_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/CCM.0000000000004206","volume":"48","author":"SM Fernando","year":"2020","unstructured":"Fernando SM, Mok G, Castellucci LA, et al. Impact of anticoagulation on mortality and resource utilization among critically ill patients with major bleeding. Crit Care Med. 2020;48:515\u201324.","journal-title":"Crit Care Med"},{"key":"2070_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1055\/s-0042-1750385","volume":"122","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao TF, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost. 2022;122:1625\u201352.","journal-title":"Thromb Haemost"},{"key":"2070_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/crj.12993","volume":"13","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Lei J, Zhai Z, et al. Comparison of prediction value of four bleeding risk scores for pulmonary embolism with anticoagulation: a real-world study in Chinese patients. Clin Respir J. 2019;13:139\u201347.","journal-title":"Clin Respir J"},{"issue":"5","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"46","key":"2070_CR12","first-page":"3258","volume":"36","author":"EC O'Brien","year":"2015","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258\u201364.","journal-title":"Eur Heart J"},{"issue":"4","key":"2070_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","volume":"58","author":"MC Fang","year":"2011","unstructured":"Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2070_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","volume":"151","author":"BF Gage","year":"2006","unstructured":"Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713\u20139.","journal-title":"Am Heart J"},{"key":"2070_CR15","doi-asserted-by":"crossref","unstructured":"vShireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130(5):1390\u20136.","DOI":"10.1378\/chest.130.5.1390"},{"issue":"2","key":"2070_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","volume":"105","author":"RJ Beyth","year":"1998","unstructured":"Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91\u20139.","journal-title":"Am J Med"},{"issue":"2","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315\u201352.","journal-title":"Chest"},{"issue":"5","key":"2070_CR18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","volume":"48","author":"FA Klok","year":"2016","unstructured":"Klok FA, H\u00f6sel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48(5):1369\u201376.","journal-title":"Eur Respir J"},{"issue":"4","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1160\/TH16-11-0830","volume":"117","author":"M Di Nisio","year":"2017","unstructured":"Di Nisio M, Raskob G, B\u00fcller HR, et al. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017;117(4):784\u201393.","journal-title":"Thromb Haemost"},{"key":"2070_CR20","doi-asserted-by":"crossref","unstructured":"Seiler E, Limacher A, Mean M, et al. Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. Thromb Haemost. 2017;117(10).","DOI":"10.1160\/TH-17-03-0162"},{"issue":"1","key":"2070_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1378\/chest.09-3081","volume":"139","author":"H Decousus","year":"2011","unstructured":"Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients. Chest. 2011;139(1):69\u201379.","journal-title":"Chest"},{"issue":"1","key":"2070_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","volume":"100","author":"N Ru\u00edz-Gim\u00e9nez","year":"2008","unstructured":"Ru\u00edz-Gim\u00e9nez N, Su\u00e1rez C, Gonz\u00e1lez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26\u201331.","journal-title":"Thromb Haemost"},{"key":"2070_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","volume":"122","author":"MA de Winter","year":"2022","unstructured":"de Winter MA, Dorresteijn J, Ageno W, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost. 2022;122:818\u201329.","journal-title":"Thromb Haemost"},{"key":"2070_CR24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1055\/s-0041-1726345","volume":"121","author":"AN Frei","year":"2021","unstructured":"Frei AN, Stalder O, Limacher A, et al. Comparison of bleeding risk scores in elderly patients receiving extended anticoagulation with vitamin K antagonists for venous thromboembolism. Thromb Haemost. 2021;121:1512\u201322.","journal-title":"Thromb Haemost"},{"key":"2070_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/a-1339-9987","volume":"41","author":"S Nopp","year":"2021","unstructured":"Nopp S, Ay C. Bleeding risk assessment in patients with venous thromboembolism. Hamostaseologie. 2021;41:267\u201374.","journal-title":"Hamostaseologie"},{"key":"2070_CR26","doi-asserted-by":"publisher","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","volume":"126","author":"MN Levine","year":"2004","unstructured":"Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S-310S.","journal-title":"Chest"},{"key":"2070_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1060028020933186","volume":"54","author":"S Tchen","year":"2020","unstructured":"Tchen S, Ryba N, Patel V, et al. Validation of bleeding risk prediction scores for patients with major bleeding on direct oral anticoagulants. Ann Pharmacother. 2020;54:1175\u201384.","journal-title":"Ann Pharmacother"},{"key":"2070_CR28","doi-asserted-by":"publisher","first-page":"e250502","DOI":"10.1371\/journal.pone.0250502","volume":"16","author":"M Alammari","year":"2021","unstructured":"Alammari M, Sultana K, Alturaiki A, et al. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population. PLoS ONE. 2021;16:e250502.","journal-title":"PLoS ONE"},{"key":"2070_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.chest.2021.08.050","volume":"161","author":"SM Fernando","year":"2022","unstructured":"Fernando SM, Tran A, Cheng W, et al. VTE prophylaxis in critically ill adults. Chest. 2022;161:418\u201328.","journal-title":"Chest"},{"key":"2070_CR30","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/europace\/euac020","volume":"24","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao TF, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace. 2022;24:1844\u201371.","journal-title":"Europace"},{"key":"2070_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/joim.13712","volume":"294","author":"SK Glise","year":"2023","unstructured":"Glise SK, Schulman S, Rosengren A, et al. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study. J Intern Med. 2023;294:743\u201360.","journal-title":"J Intern Med"},{"key":"2070_CR32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.amjcard.2017.06.058","volume":"120","author":"H Zulkifly","year":"2017","unstructured":"Zulkifly H, Lip G, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol. 2017;120:1139\u201345.","journal-title":"Am J Cardiol"},{"key":"2070_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","volume":"131","author":"Y Guo","year":"2018","unstructured":"Guo Y, Zhu H, Chen Y, et al. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med. 2018;131:185\u201392.","journal-title":"Am J Med"},{"key":"2070_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","volume":"199","author":"MA de Winter","year":"2021","unstructured":"de Winter MA, van Es N, Buller HR, et al. Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal. Thromb Res. 2021;199:85\u201396.","journal-title":"Thromb Res"},{"key":"2070_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejim.2018.12.004","volume":"61","author":"N Vicente-Ibarra","year":"2019","unstructured":"Vicente-Ibarra N, Marin F, Pernias-Escrig V, et al. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. Eur J Intern Med. 2019;61:48\u201353.","journal-title":"Eur J Intern Med"},{"key":"2070_CR36","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S\u2013e496S.","journal-title":"Chest"},{"key":"2070_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/00313020126304","volume":"33","author":"BK Ip","year":"2001","unstructured":"Ip BK, Thomson AR, Moriarty HT. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology. 2001;33:347\u201352.","journal-title":"Pathology"},{"key":"2070_CR38","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s11239-020-02092-w","volume":"50","author":"E Wojakowski","year":"2020","unstructured":"Wojakowski E, Cheruvil C, Hassan A, et al. Albumin and bleed risk in rivaroxaban treated patients. J Thromb Thrombolysis. 2020;50:1004\u201311.","journal-title":"J Thromb Thrombolysis"},{"key":"2070_CR39","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.clinthera.2009.07.015","volume":"31","author":"AH Abdelhafiz","year":"2009","unstructured":"Abdelhafiz AH, Myint MP, Tayek JA, et al. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther. 2009;31:1534\u20139.","journal-title":"Clin Ther"},{"issue":"14","key":"2070_CR40","doi-asserted-by":"publisher","first-page":"e41935","DOI":"10.1097\/MD.0000000000041935","volume":"104","author":"C Chen","year":"2025","unstructured":"Chen C, Fan H, Shuai R. Analysis of risk factors for gastrointestinal bleeding in percutaneous coronary intervention patients treated with dual antiplatelet therapy after surgery. Med. 2025;104(14):e41935.","journal-title":"Med"},{"key":"2070_CR41","doi-asserted-by":"publisher","first-page":"1618626","DOI":"10.3389\/fmed.2025.1618626","volume":"12","author":"X Fu","year":"2025","unstructured":"Fu X, Ren H, Yang Y, et al. Analysis of influencing factors and construction of predictive model for major gastrointestinal bleeding after receiving VTE prophylactic anticoagulants in non-tumor patients. Front Med. 2025;12:1618626.","journal-title":"Front Med"},{"key":"2070_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000534522","volume":"64","author":"A Korytny","year":"2023","unstructured":"Korytny A, Mazzawi F, Marcusohn E, et al. Admission hypocalcemia and the need for endoscopic and clinical interventions among patients with upper gastrointestinal bleeding. Eur Surg Res. 2023;64:398\u2013405.","journal-title":"Eur Surg Res"},{"key":"2070_CR43","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/jamaneurol.2016.2252","volume":"73","author":"A Morotti","year":"2016","unstructured":"Morotti A, Charidimou A, Phuah CL, et al. Association between serum calcium level and extent of bleeding in patients with intracerebral hemorrhage. JAMA Neurol. 2016;73:1285\u201390.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2070_CR44","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s11739-021-02671-6","volume":"16","author":"A Korytny","year":"2021","unstructured":"Korytny A, Klein A, Marcusohn E, et al. Hypocalcemia is associated with adverse clinical course in patients with upper gastrointestinal bleeding. Intern Emerg Med. 2021;16(7):1813\u201322.","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2070_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00268-005-0374-5","volume":"30","author":"T Uruno","year":"2006","unstructured":"Uruno T, Miyauchi A, Shimizu K, et al. A prophylactic infusion of calcium solution reduces the risk of symptomatic hypocalcemia in patients after total thyroidectomy. World J Surg. 2006;30(3):304\u20138.","journal-title":"World J Surg"},{"key":"2070_CR46","doi-asserted-by":"crossref","unstructured":"Brown RB, Klar J, Lemeshow S, et al. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986;146:2159\u201364.","DOI":"10.1001\/archinte.1986.00360230079013"},{"key":"2070_CR47","first-page":"e158407","volume":"11","author":"LJ Chen","year":"2016","unstructured":"Chen LJ, Hsiao FY, Shen LJ, et al. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study. PLoS ONE. 2016;11:e158407.","journal-title":"PLoS ONE"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02070-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:05:53Z","timestamp":1778749553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02070-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7635200\/v1","asserted-by":"object"}]},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the Ethics Committee of the Linping Campus, the Second Affiliated Hospital, Zhejiang University School of Medicine (approval number: 2024\u201302-027; approved 22 Feb 2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}